Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.

CONCLUSIONS: Response rates were low regardless of monotherapy or combination strategies. No new safety signals were identified. Including use of a tumor-based interferon-γ signature and change in baseline and on-treatment circulating tumor DNA are clinically feasible and may be novel strategies to improve treatment response in this difficult-to-treat population.
PMID: 31676670 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 31, 2019 Category: Cancer & Oncology Authors: Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn P, He P, McDevitt J, Sheth S, Englert JM, Ku GY Tags: Clin Cancer Res Source Type: research